Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Bought by Fmr LLC

Fmr LLC lifted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 30.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 81,983,231 shares of the company’s stock after acquiring an additional 19,242,468 shares during the quarter. Fmr LLC owned 7.24% of Teva Pharmaceutical Industries worth $1,806,910,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Stifel Financial Corp raised its stake in shares of Teva Pharmaceutical Industries by 54.0% during the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock worth $1,196,000 after buying an additional 23,283 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its holdings in Teva Pharmaceutical Industries by 7.2% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock worth $10,983,000 after acquiring an additional 33,277 shares during the period. Pinnbrook Capital Management LP purchased a new position in Teva Pharmaceutical Industries in the fourth quarter worth $4,966,000. Asset Management One Co. Ltd. lifted its holdings in Teva Pharmaceutical Industries by 14.6% in the fourth quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company’s stock valued at $10,414,000 after acquiring an additional 58,413 shares during the period. Finally, CWA Asset Management Group LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth $3,340,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Barclays reduced their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. UBS Group reduced their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Friday. Bank of America reduced their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, March 6th. Finally, Piper Sandler upped their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.43.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $13.83 on Monday. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.51 and a fifty-two week high of $22.80. The company has a market capitalization of $15.68 billion, a price-to-earnings ratio of -9.54, a PEG ratio of 1.44 and a beta of 0.82. The stock has a fifty day moving average of $16.52 and a two-hundred day moving average of $18.01. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.